We are seeing patients in-person and through Video Visits. Learn more about how we’re keeping you safe and please review our updated visitor policy. Please also consider supporting Weill Cornell Medicine’s efforts to support our front-line workers.
Sandra and Edward Meyer Cancer Center

Warning message

The subscription service is currently unavailable. Please try again later.

You are here


Classifying T-cell lymphomas

Tuesday, May 9, 2017

Jia Ruan, M.D., Ph.D., associate professor of Clinical Medicine, spoke to OncLive about the classification of T-cell lymphomas. T-cell lymphoma is a very rare subtype; approximately 5% to 10% of patients with non-Hodgkin lymphoma have this disease, Ruan explains.

It is also very heterogenous and difficult to treat. The long-term outcomes for patients with T-cell lymphoma remain to be suboptimal. Studies show that there is a 20% to 30% 5-year overall survival rate, so there is room for improvement, she adds.

Ongoing clinical trials in this area are focused on intensifying chemotherapy regimens or incorporating novel agents to improve effectiveness and induce complete remissions.

OncLive also featured a more extensive interview here.